Edition:
United States

Female Health Co (FHCO.OQ)

FHCO.OQ on NASDAQ Stock Exchange Capital Market

1.23USD
4:00pm EDT
Change (% chg)

$0.03 (+2.50%)
Prev Close
$1.20
Open
$1.18
Day's High
$1.24
Day's Low
$1.18
Volume
23,088
Avg. Vol
12,509
52-wk High
$1.64
52-wk Low
$0.74

FHCO.OQ

Chart for FHCO.OQ

About

The Female Health Company is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men's and women's health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices,... (more)
No analyst recommendations are available for FHCO.OQ.

Overall

Beta: 1.35
Market Cap(Mil.): $37.61
Shares Outstanding(Mil.): 31.34
Dividend: --
Yield (%): --

Financials

  FHCO.OQ Industry Sector
P/E (TTM): -- 75.20 41.26
EPS (TTM): -0.14 -- --
ROI: -9.74 10.06 53.07
ROE: -12.65 13.97 60.75

BRIEF-Female Health Co enters into a fourth amendment to its credit agreement

* Female Health Co says on May 15, 2017, co entered into a fourth amendment, dated effective as of March 30, 2017 to its credit agreement - SEC filing

May 19 2017

BRIEF-Female Health director Bethune buys 10,000 shares of co's common stock on May 15

* Female Health Co director David Bethune reports purchase of 10,000 shares of co's common stock on May 15 at average price of $1.03 per share - SEC filing Source text: (http://bit.ly/2rfgSZv) Further company coverage:

May 17 2017

BRIEF-Female Health Co says new Tamsulosin DRS formulation advances to stage 2

* The Female Health Company / Veru Healthcare announces successful stage 1 of the clinical trial to evaluate bioequivalence between Tamsulosin DRS and FLOMAX®

Apr 12 2017

BRIEF-Female Health Co initiates bioequivalence clinical trial

* The Female Health Company / Veru Healthcare initiates bioequivalence clinical trial comparing tamsulosin drs with flomax®

Mar 09 2017

BRIEF-FEMALE HEALTH COMPANY REPORTS Q1 LOSS PER SHARE $0.04

* THE FEMALE HEALTH COMPANY / VERU HEALTHCARE REPORTS FISCAL 2017 FIRST-QUARTER FINANCIAL RESULTS

Feb 09 2017

BRIEF-Female Health Company launches PREBOOST for premature ejaculation

* Female Health Company / Veru Healthcare launches preboost for premature ejaculation Source text for Eikon: Further company coverage:

Jan 06 2017

BRIEF-Female Health Co says BMO Harris Bank approves to maintain $10 mln credit facility

* The Female Health Company / Veru Healthcare announces that BMO Harris Bank, N.A. approves amendment to maintain existing $10 million credit facility

Nov 29 2016

More From Around the Web

Competitors

Earnings vs. Estimates